Certara, Inc.的Simcyp®模拟器在针对慢性髓系白血病（CML）治疗药物Asciminib的研究中取得重大突破。其模拟结果成功取代了传统所需的十项人体临床试验，显著提升了药物研发效率。这一进展不仅展示了计算模型在药物开发领域的强大潜力，也为加速创新疗法问世提供了新的路径。
Certara, Inc.的Simcyp®模拟器在针对慢性髓系白血病（CML）治疗药物Asciminib的研究中取得重大突破。其模拟结果成功取代了传统所需的十项人体临床试验，显著提升了药物研发效率。这一进展不仅展示了计算模型在药物开发领域的强大潜力，也为加速创新疗法问世提供了新的路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.